Showing results (181-190 of 234) with videos related to

Sort By:
Pageof 24
Lancet (London, England)|September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialMichael J Morris, Daniel Castellano, Ken Herrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
JAMA Oncology|September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical TrialSrikala S Sridhar, Normand Blais, Ben Tran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II TrialDaniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
European Urology|May 27, 2020
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate CancerCameron Herberts, Andrew J Murtha, Simon Fu, et al.
Nature Communications|October 30, 2022
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumorsSujun Chen, Jessica Petricca, Wenbin Ye, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
Pageof 24